Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Del Rio

Internal Medicine Dracut, MA Medical Doctor

NPI 1285608398 CMS profile 103840

505 Nashua Rd, Suite 1, Dracut, MA 01826

Open in the dashboard

General payments

$3,739

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Del Rio of Dracut, MA is reported in the CMS Open Payments database as having received $3,739 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $514 25
2024 General $721 39
2023 General $259 13
2022 General $81 4
2021 General $237 15
2020 General $563 32
2019 General $1,364 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Del Rio
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carlos Del Rio were reported at $514. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carlos Del Rio Internal Medicine median Middle half National median
2019 $1,364 $159 $48–$570 $163
2020 $563 $119 $33–$402 $114
2021 $237 $135 $37–$521 $132
2022 $81 $141 $42–$496 $149
2023 $259 $149 $45–$519 $160
2024 $721 $154 $47–$537 $164
2025 $514 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $534 29 payments
  2. AstraZeneca Pharmaceuticals LP $452 26 payments
  3. AbbVie, Inc. $377 22 payments
  4. Astellas Pharma US Inc $306 10 payments
  5. Janssen Pharmaceuticals, Inc $233 10 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $221 10 payments
  7. Lilly USA, LLC $200 12 payments
  8. Otsuka America Pharmaceutical, Inc. $183 9 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $158 10 payments
  10. GlaxoSmithKline, LLC. $145 8 payments
  11. Other $929 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,530 196 payments
  2. Education $209 5 payments
Products named General payments · program years 2019–2025
  1. PREVNAR 20 $246 12 payments
  2. COMIRNATY $246 12 payments
  3. XARELTO $233 10 payments
  4. VRAYLAR $233 14 payments
  5. ABRYSVO $225 11 payments
  6. INVOKANA $208 9 payments
  7. REXULTI $183 9 payments
  8. CHANTIX $169 11 payments
  9. Kerendia $158 10 payments
  10. BREZTRI $151 8 payments
  11. Other $2,936 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

6,932

Median for Internal Medicine: 777

Drug cost

$521,756

Median for Internal Medicine: $73,373

Branded share of claims

15.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 77 $88,365
Jardiance Empagliflozin Brand 54 $65,114
Trulicity Dulaglutide Brand 28 $50,631
Xarelto Rivaroxaban Brand 30 $33,078
Linzess Linaclotide Brand 26 $24,314
Ozempic Semaglutide Brand 21 $22,835
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $21,974
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $21,830
Januvia Sitagliptin Phosphate Brand 12 $15,259
Mounjaro Tirzepatide Brand 12 $12,429

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$96,202

Medicare's payments for the services billed

Medicare patients

334

Average age 71

Services billed

1,663

153 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 28%
Diabetes 24%
Depression 23%
Ischemic heart disease 18%
Heart failure 13%
Chronic kidney disease 13%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $138
$138 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $122
$122 — —
VRAYLAR
  • AbbVie, Inc. $109
$109 — —
Veozah
  • Astellas Pharma US Inc $56
$56 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $41
$41 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record